Topic: contract manufacturer
The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.
So far, manufacturing has been a hurdle for drugmakers in the burgeoning CAR-T field—but WuXi AppTec is doing its best to change that.
Boston-based private equity firm TA Associations is close to a deal to buy a minority stake in CDMO Piramal Pharma for up to $500 million.
Abraxane has been kicked out of a bulk procurement program in China after Chinese authorities found fault at a Fresnius Kabi facility in the U.S.
It took three attempts, but Acacia Pharma has now won FDA approval of Barhemsys, its PONV drugs after its CDMO was finally approved to make the API.
Catalent, which carved out a place in gene therapies with its $1.2 billion Paragon Services deal, is now buying Masthercell Global for $315 million.
China is repurposing existing drugs for coronavirus. South Korea arrested a Sanofi exec for a vaccine case. Novartis outlined ambitious China plan.
Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.
Boehringer Ingelheim's leap of faith in China has paid off with the German company's production of a PD-1 for BeiGene.
Teva will produce its new migraine drug at a plant in Israel and more news of note.